Pfizer shoots back at Alnylam's claims in high-stakes COVID-19 vaccine patent case

In a patent fight surrounding the U.S.' first—and most lucrative—COVID-19 vaccine, Pfizer has shot back at Alnylam’s infringement argument. After Alnylam sued alleging unauthorized use of its delivery technology, Pfizer says the company's tech was irrelevant to its shot's success.